Positive patch test findings after the initiation of dupilumab therapy, an interleukin-4α receptor inhibitor used for moderate-to-severe or recalcitrant atopic dermatitis (AD), have recently been reported,1,2 suggesting that the allergic contact dermatitis (ACD) pathway is not inhibited by dupilumab. We present a case that suggests that the response to dupilumab therapy may be nuanced and that there may be an allergen-specific response.
Raffi J, Botto N. Patch Testing and Allergen-Specific Inhibition in a Patient Taking Dupilumab. JAMA Dermatol. 2019;155(1):120–121. doi:10.1001/jamadermatol.2018.4098
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: